Cangrelor: Additional Phase III data

Additional data from the double-blind, U.S. Phase III CHAMPION PHOENIX trial in 10,942 evaluable patients undergoing PCI showed that IV cangrelor significantly reduced the composite primary endpoint of all-cause mortality, MI, ischemia-driven revascularization and stent thrombosis at 48 hours by 22% vs. Plavix clopidogrel (4.7% vs. 5.9%, p=0.005). On secondary endpoints, cangrelor significantly reduced the incidence of stent

Read the full 588 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers